Name (Synonyms) | Correlation | |
---|---|---|
drug160 | Anakinra +/- Ruxolitinib (stages 2b/3) Wiki | 0.71 |
drug2529 | Tocilizumab +/- ruxolitinib (stages 2b/3) Wiki | 0.71 |
drug3010 | standard procedure Wiki | 0.71 |
drug2537 | Tocilizumab and Ruxolitinib (Advanced stage 3) Wiki | 0.71 |
drug165 | Anakinra and Ruxolitinib (Advanced stage 3) Wiki | 0.71 |
drug2326 | Standard of care Wiki | 0.16 |
There are 2 clinical trials
This study plans to learn more about the effects of Dornase Alfa in COVID19 (coronavirus disease of 2019) patients, the medical condition caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Dornase Alfa is a FDA-approved drug for the treatment of cystic fibrosis, which facilitates mucus clearance by cutting apart neutrophil-derived extracellular double-stranded DNA. This study intends to define the impact of aerosolized intra-tracheal Dornase Alfa administration on the severity and progression of acute respiratory distress syndrome (ARDS) in COVID-19 patients. This drug might make lung mucus thinner and looser, promoting improved clearance of secretions and reduce extracellular double-stranded DNA-induced hyperinflammation in alveoli, preventing further damage to the lungs. The study will recruit mechanically ventilated patients hospitalized in ICU who have been diagnosed with COVID-19 and meet ARDS criteria. It is a prospective, randomized, controlled, multicentric, open-label clinical trial. The goal is to recruit 100 patients.
Description: The primary endpoint is the occurrence of at least one grade improvement between D0 (inclusion) and D7 in the ARDS scale severity (Berlin criteria). For instance from severe to moderate or from moderate to mild
Measure: Efficacy of intratracheal administration: occurrence of at least one grade improvement Time: Day 7An open-label, randomised, Best-Available-Care (BAC) and historic-controlled trial of nebulised dornase alfa [2.5 mg BID] for 7 days in participants with COVID-19 who are admitted to hospital and are at risk of ventilatory failure (the COVASE study). Controls will include a randomised arm to receive BAC, historic data from UCLH patients with COVID-19 and biobanked samples will be used to demonstrate an effect of dornase alfa. CRP will be measured to assess the effect of dornase alfa on inflammation. Clinical endpoints and biomarkers (e.g. d-dimer) will be used to assess the clinical response. Exploratory endpoints will explore the effects of dornase alfa on features of neutrophil extracellular traps (NETs).
Description: Analysing stabilisation of C-reactive protein
Measure: Measuring the change in inflammation Time: 7 daysDescription: How many patients that are still alive
Measure: Number of patients that are alive at 28 days Time: 28 daysDescription: How many days on oxygen
Measure: Amount of days that patient requires oxygen Time: 7 daysDescription: Calculating index with Fi02, mean airways pressure and Pa02 via https://www.mdcalc.com/oxygenation-index#use-cases
Measure: Average oxygenation index Time: 7 daysDescription: How many days as an inpatient
Measure: Days patient admitted to hospital Time: 7 daysDescription: How many patients require mechanical ventilation
Measure: Percentage of patients that need mechanical ventilation Time: 7 days